Health Care·Pharmaceuticals·$9.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.26 | N/A | +76.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.26 | N/A | +76.97% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to continuing development efforts.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
Axovant Gene Therapies reported a narrower-than-expected loss per share, which led to a positive stock reaction, increasing by 5.41%. The company did not provide revenue figures or future guidance, leaving investors focused on the EPS surprise. Overall, the results indicate progress in their operations, but the lack of revenue data may raise some concerns about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UBIQUITI INC
May 5, 2023